Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication

Antiviral Research

Volumn 99, Issue 2, 2013, Pages 165-171

  van Cleef, Koen W R ^a   Overheul, Gijs J ^a   Thomassen, Michael C ^a   Kaptein, Suzanne J F ^b   Davidson, Andrew D ^c   Jacobs, Michael ^d   Neyts, Johan ^b   van Kuppeveld, Frank J M ^a   van Rij, Ronald P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antiviral therapy; Dengue virus; Naltrindole; NS4B; SDM25N

Indexed keywords

ANTIVIRUS AGENT; DELTA OPIATE RECEPTOR ANTAGONIST; GENOMIC RNA; NALTRINDOLE; NONSTRUCTURAL PROTEIN 4B; SDM 25N; UNCLASSIFIED DRUG;

AEDES ALBOPICTUS; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; DENGUE VIRUS; DENGUE VIRUS 2; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPLICON; RNA REPLICATION; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

50% EFFECTIVE CONCENTRATION; ANTIVIRAL THERAPY; CCID50; CELL CULTURE INFECTIOUS DOSE 50%; CPE; CYTOPATHIC EFFECT; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; DENV; DHF; EC(50); FMDV; FOOT-AND-MOUTH DISEASE VIRUS; HOURS POST-INFECTION; HOURS POST-TRANSFECTION; HPI; HPT; IFN; INTERFERON; NALTRINDOLE; NCC; NGC; NIH CLINICAL COLLECTION; NS4B; SDM25N; STRAIN NEW GUINEA C;

AEDES; AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CRICETINAE; DENGUE; DENGUE VIRUS; DRUG RESISTANCE, VIRAL; HELA CELLS; HUMANS; MUTATION; NALTREXONE; NUCLEIC ACID SYNTHESIS INHIBITORS; REPLICON; RNA, VIRAL; SMALL MOLECULE LIBRARIES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

AEDES ALBOPICTUS; ARBOVIRUS; DENGUE VIRUS;

EID: 84879246944     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.05.011     Document Type: Article

References (28)

1. Alvarez D.E., De Lella Ezcurra A.L., Fucito S., Gamarnik A.V. Role of RNA structures present at the 3'UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology 2005, 339:200-212.
2. Belov G.A., Altan-Bonnet N., Kovtunovych G., Jackson C.L., Lippincott-Schwartz J., Ehrenfeld E. Hijacking components of the cellular secretory pathway for replication of poliovirus RNA. J. Virol. 2007, 81:558-567.
3. Botting C., Kuhn R.J. Novel approaches to flavivirus drug discovery. Expert Opin. Drug Discov. 2012, 7:417-428.
4. Desmyter J., Melnick J.L., Rawls W.E. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J. Virol. 1968, 2:955-961.
5. 1-interferon genes in human leukemia and derived cell lines. Proc. Natl. Acad. Sci. USA 1988, 85:5259-5263.
6. Emeny J.M., Morgan M.J. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J. Gen. Virol. 1979, 43:247-252.
7. Franco C., Hynes N.A., Bouri N., Henderson D.A. The dengue threat to the United States. Biosecur. Bioterror. 2010, 8:273-276.
8. Gjenero-Margan I., Aleraj B., Krajcar D., Lesnikar V., Klobučar A., Pem-Novosel I., Kurečić-Filipović S., Komparak S., Martić R., Duričić S., Betica-Radić L., Okmadžić J., Vilibić-Čavlek T., Babić-Erceg A., Turković B., Avšić-Županc T., Radić I., Ljubić M., Šarac K., Benić N., Mlinarić-Galinović G. Autochthonous dengue fever in Croatia, August-September 2010. Euro Surveill. 2011, 16:19805.
9. Gualano R.C., Pryor M.J., Cauchi M.R., Wright P.J., Davidson A.D. Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA. J. Gen. Virol. 1998, 79:437-446.
10. Guzman A., Istúriz R.E. Update on the global spread of dengue. Int. J. Antimicrob. Agents 2010, 36S:S40-S42.
11. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., Hunsperger E., Kroeger A., Margolis H.S., Martínez E., Nathan M.B., Pelegrino J.L., Simmons C., Yoksan S., Peeling R.W. Dengue: a continuing global threat. Nat. Rev. Microbiol. 2010, 8:S7-S16.
12. Habjan M., Penski N., Spiegel M., Weber F. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. J. Gen. Virol. 2008, 89:2157-2166.
13. Holden K.L., Stein D.A., Pierson T.C., Ahmed A.A., Clyde K., Iversen P.L., Harris E. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3' stem-loop structure. Virology 2006, 344:439-452.
14. Julander J.G., Perry S.T., Shresta S. Important advances in the field of anti-dengue virus research. Antivir. Chem. Chemother. 2011, 21:105-116.
15. Kaptein S.J.F., De Burghgraeve T., Froeyen M., Pastorino B., Alen M.M.F., Mondotte J.A., Herdewijn P., Jacobs M., de Lamballerie X., Schols D., Gamarnik A.V., Sztaricskai F., Neyts J. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob. Agents Chemother. 2010, 54:5269-5280.
16. La Ruche G., Souarès Y., Armengaud A., Peloux-Petiot F., Delaunay P., Desprès P., Lenglet A., Jourdain F., Leparc-Goffart I., Charlet F., Ollier L., Mantey K., Mollet T., Fournier J.P., Torrents R., Leitmeyer K., Hilairet P., Zeller H., Van Bortel W., Dejour-Salamanca D., Grandadam M., Gastellu-Etchegorry M. First two autochthonous dengue virus infections in metropolitan France, September 2010. Euro Surveill. 2010, 15:19676.
17. Massé N., Davidson A., Ferron F., Alvarez K., Jacobs M., Romette J.L., Canard B., Guillemot J.C. Dengue virus replicons: production of an interserotypic chimera and cell lines from different species, and establishment of a cell-based fluorescent assay to screen inhibitors, validated by the evaluation of ribavirin's activity. Antiviral Res. 2010, 86:296-305.
18. McLamore S., Ullrich T., Rothman R.B., Xu H., Dersch C., Coop A., Davis P., Porreca F., Jacobson A.E., Rice K.C. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5a-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy. J. Med. Chem. 2001, 44:1471-1474.
19. Miller S., Sparacio S., Bartenschlager R. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J. Biol. Chem. 2006, 281:8854-8863.
20. Mosca J.D., Pitha P.M. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol. Cell. Biol. 1986, 6:2279-2283.
21. Muñoz-Jordán J.L., Laurent-Rolle M., Ashour J., Martínez-Sobrido L., Ashok M., Lipkin W.I., García-Sastre A. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 2005, 79:8004-8013.
22. Muñoz-Jordán J.L., Sánchez-Burgos G.G., Laurent-Rolle M., García-Sastre A. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. USA 2003, 100:14333-14338.
23. Noble C.G., Chen Y.L., Dong H., Gu F., Lim S.P., Schul W., Wang Q.Y., Shi P.Y. Strategies for development of dengue virus inhibitors. Antiviral Res. 2010, 85:450-462.
24. Patkar C.G., Larsen M., Owston M., Smith J.L., Kuhn R.J. Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay. Antimicrob. Agents Chemother. 2009, 53:4103-4114.
25. Pryor M.J., Carr J.M., Hocking H., Davidson A.D., Li P., Wright P.J. Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am. J. Trop. Med. Hyg. 2001, 65:427-434.
26. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 1938, 27:493-497.
27. WHO, 2013. Global alert and response (GAR). Dengue/dengue haemorrhagic fever. Available from: (accessed May 2013). http://www.who.int/csr/disease/dengue/en/index.html.
28. Xie X., Wang Q.Y., Xu H.Y., Qing M., Kramer L., Yuan Z., Shi P.Y. Inhibition of dengue virus by targeting viral NS4B protein. J. Virol. 2011, 85:11183-11195.